Treatment Response Prediction Report

Anneleen Daemen and Obi Griffith (PI: Spellman/Gray)

February 10, 2012

Sample Information:

Expression File: Expression_test_tumor.txt
Methylation File: Meth_test_tumor.txt
Copy Number File: CNV_test_tumor.txt

Recommended Treatment:

MLN4924

Treatment Response Predictions:[1]

Treatment	Model	AUC	Data	WPMV[2]	Probability	Sensitivity
MLN4924	LSSVM	0.696	EA-Meth	92	0.930	+
Oxamflatin	LSSVM	0.610	U133A	100	0.930	+
5-FdUR	LSSVM	0.655	U133A	100	0.920	+
PD98059(LC Labs)	RF	0.742	U133A	100	0.898	+
Geldanamycin	LSSVM	0.675	U133A-Meth	100	0.847	+
BIBW2992	LSSVM	0.919	SNP	100	0.726	+
SB-715992	RF	0.651	SNP	100	0.656	+
Ixabepilone	RF	0.772	EA-Meth	93	0.626	+
GSK2141795c	RF	0.850	Meth-SNP	100	0.619	+
GSK1059868A	RF	0.785	RS-Meth-SNP	96	0.614	+
Paclitaxel	RF	0.728	U133A-Meth-SNP	100	0.603	+
SKI-606(Bosutinib)	RF	0.732	U133A-SNP	100	0.595	+
Vinorelbine	RF	0.720	U133A	100	0.587	+
GSK2 (PLKi)	RF	0.881	U133A-SNP	100	0.587	+
Imatinib	LSSVM	0.699	SNP	100	0.581	+
PF-4691502	RF	0.762	EA-Meth	90	0.578	+
Docetaxel	RF	0.832	Meth	100	0.561	+
API-2(Tricir)	RF	0.809	Meth-SNP	100	0.555	+
Carboplatin	RF	0.620	RS-Meth-SNP	95	0.554	+
SAHA (Vorinostat)	RF	0.771	U133A-Meth	100	0.542	+
CGC-11047	RF	0.824	RS-Meth-SNP	96	0.505	+
IKK 16	RF	0.706	Meth	100	0.498	-
AS-252424	RF	0.740	EA-Meth	90	0.482	-
ERKi II (FR180304)	RF	0.604	Meth	100	0.481	-
AG1478	LSSVM	0.753	SNP	100	0.475	-

---

[1]Patient considered sensitive to treatment if probability is greater than 0.5

[2]Weighted percent model variables present in input data

[3]Code location: /Users/adaemen/Dropbox/drug_predictors/Rscripts/Rtoolbox/DrugResponseToolboxAgnostic_mac.R

Treatment Response Predictions:[1]

Treatment	Model	AUC	Data	WPMV[2]	Probability	Sensitivity
Mebendazole	LSSVM	0.688	EA-Meth-SNP	93	0.461	-
GSK1838705A (IGF1R)	RF	0.683	Meth-SNP	100	0.437	-
GSK (CENPE)	LSSVM	0.742	U133A-Meth	100	0.434	-
Tykerb_IGF1R (1_1)	RF	0.793	EA-Meth	90	0.425	-
NSC663284	RF	0.722	U133A-Meth-SNP	100	0.418	-
VX-680	RF	0.679	Meth-SNP	100	0.415	-
TCS PIM-11	RF	0.735	U133A-Meth	100	0.414	-
PF-3814735	RF	0.753	RS-Meth-SNP	97	0.386	-
Glycyl H1152	RF	0.728	RS-Meth-SNP	97	0.372	-
PF-2341066	RF	0.733	RS-Meth-SNP	97	0.357	-
ICRF-193	RF	0.750	RS-Meth	96	0.347	-
SB-3CT	RF	0.678	RS-Meth-SNP	97	0.324	-
NU6102	RF	0.778	SNP	100	0.269	-
Baicalein	LSSVM	0.620	Meth	100	0.235	-
MG-132	LSSVM	0.641	U133A-Meth	100	0.197	-
Iressa	LSSVM	0.801	SNP	100	0.175	-
Rafi IV (L779450)	RF	0.658	U133A	100	0.164	-
AZD6244	LSSVM	0.650	U133A-Meth-SNP	100	0.048	-
Tamoxifen	LSSVM	0.721	U133A	100	0.045	-
GSK-AUR1	LSSVM	0.711	U133A-Meth	100	0.001	-
17-AAG	LSSVM	0.596	EA	30	NA	NA
5-FU	LSSVM	0.766	RS-Meth	62	NA	NA
AKT1-2 inhibitor	RF	0.938	EA	36	NA	NA
BEZ235	RF	0.485	RS-SNP	27	NA	NA
Bortezomib-batch1	RF	0.739	RS	16	NA	NA
Bortezomib-batch2	LSSVM	0.719	RS-SNP	26	NA	NA
CGC-11144	LSSVM	0.418	Meth	100	NA	NA
CPT-11(FD)	RF	0.699	EA-SNP	41	NA	NA
Cisplatin	RF	0.745	RS	16	NA	NA
Disulfiram	RF	0.718	RS-SNP	28	NA	NA
Doxorubicin(FD)	RF	0.726	RS-SNP	28	NA	NA
Epirubicin	RF	0.739	RS-SNP	29	NA	NA
Erlotinib	LSSVM	0.685	RS-SNP	32	NA	NA
Etoposide	LSSVM	0.770	EA-SNP	37	NA	NA
Everolimus	RF	0.852	RS-SNP	26	NA	NA
FTase inhibitor I	RF	0.701	EA	37	NA	NA
Fascaplysin	LSSVM	0.751	RS	16	NA	NA
GSK-MEKi	LSSVM	0.775	RS-SNP	14	NA	NA
GSK2119563A	RF	0.821	EA	34	NA	NA
GSK2126458A	RF	0.907	EA	35	NA	NA
GSK615B(PI3Ki)	LSSVM	0.776	RS	22	NA	NA
GSK650394A	LSSVM	0.590	SNP	100	NA	NA

[1]Patient considered sensitive to treatment if probability is greater than 0.5

[2]Weighted percent model variables present in input data

Treatment Response Predictions (continued):[1]

Treatment	Model	AUC	Data	WPMV[2]	Probability	Sensitivity
GSK_Tykerb	LSSVM	0.953	EA	70	NA	NA
Gemcitabine	LSSVM	0.639	RS-SNP	37	NA	NA
Ibandronate sodium salt	LSSVM	0.656	EA	36	NA	NA
LBH589	RF	0.788	RS-SNP	25	NA	NA
Lestaurtinib(CEP-701)	RF	0.591	SNP	100	NA	NA
Methotrexate	LSSVM	0.615	RS-SNP	26	NA	NA
Nelfinavir	LSSVM	0.468	EA	38	NA	NA
Nutlin 3a	LSSVM	0.745	RS	16	NA	NA
Olomoucine II	LSSVM	0.683	RS	14	NA	NA
Oxaliplatin	RF	0.672	EA-SNP	42	NA	NA
PF-3084014	RF	0.745	EA	36	NA	NA
Pemetrexed	LSSVM	0.549	Meth-SNP	100	NA	NA
Purvalanol A	RF	0.661	EA-SNP	43	NA	NA
Rapamycin	RF	0.803	RS-SNP	29	NA	NA
Sorafenib	RF	0.678	RS	17	NA	NA
Sunitinib Malate	LSSVM	0.623	RS	23	NA	NA
TCS2312 dihydrochloride	RF	0.697	RS	16	NA	NA
TPT(FD)	RF	0.593	EA-SNP	42	NA	NA
Temsirolimus(Torisel)	RF	0.596	RS	17	NA	NA
Trichostatin A	LSSVM	0.699	RS-SNP	24	NA	NA
Valproic acid	RF	0.685	RS-SNP	25	NA	NA
Velcade	LSSVM	0.541	U133A	100	NA	NA
XRP44X	LSSVM	0.586	SNP	100	NA	NA
ZM447439	LSSVM	0.523	EA	27	NA	NA

---

[1] Patient considered sensitive to treatment if probability is greater than 0.5

[2] Weighted percent model variables present in input data